Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash & Equivalents: 2018-2024

Historic Cash & Equivalents for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $543.1 million.

  • Revolution Medicines' Cash & Equivalents rose 8.04% to $217.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.4 million, marking a year-over-year increase of 8.04%. This contributed to the annual value of $543.1 million for FY2024, which is 21.99% down from last year.
  • Per Revolution Medicines' latest filing, its Cash & Equivalents stood at $543.1 million for FY2024, which was down 21.99% from $696.1 million recorded in FY2023.
  • Revolution Medicines' 5-year Cash & Equivalents high stood at $696.1 million for FY2023, and its period low was $104.3 million during FY2020.
  • In the last 3 years, Revolution Medicines' Cash & Equivalents had a median value of $543.1 million in 2024 and averaged $466.9 million.
  • As far as peak fluctuations go, Revolution Medicines' Cash & Equivalents spiked by 525.90% in 2020, and later decreased by 21.99% in 2024.
  • Yearly analysis of 5 years shows Revolution Medicines' Cash & Equivalents stood at $104.3 million in 2020, then climbed by 4.06% to $108.5 million in 2021, then surged by 48.77% to $161.4 million in 2022, then soared by 331.29% to $696.1 million in 2023, then declined by 21.99% to $543.1 million in 2024.